Key Metrics
Total funding
IPO gross proceeds ~$155.5M (incl. private placement)
As of Jul 27, 2026Scribe Therapeutics
Company Snapshot
Scribe Therapeutics is a Biotech company, based in Alameda, California, USA, founded 2018 by Benjamin Oakes, Jennifer Doudna, Brett T. Staahl. Market cap $542.77M (As of Sep 4, 2026, stockanalysis.com). Total funding IPO gross proceeds ~$155.5M (incl. private placement) (As of Jul 27, 2026).
Recent changes
- Sep 4, 2026Sep 4, 2026First reported market cap: $542.77M stockanalysis.com
- Jul 27, 2026Jul 27, 2026First reported total funding: IPO gross proceeds ~$155.5M (incl. private placement) Scribe Therapeutics
- Jul 24, 2026Jul 24, 2026Raised $129M BioPharma Dive
- Jul 24, 2026Jul 24, 2026IPO $155.5M (incl. private placement) Scribe Therapeutics
- Jul 24, 2026Jul 24, 2026Scribe Therapeutics Prices Upsized IPO With Sanofi Backing Pulse story
Earlier changes (6)
- Jul 23, 2026Jul 23, 2026Scribe Therapeutics Soars In Rare Gene-Editing IPO Pulse story
- Jul 10, 2026Jul 10, 2026Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO Pulse story
- Jul 2, 2026Jul 2, 2026Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO Pulse story
- Jul 2, 2026Jul 2, 2026Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite Pulse story
- Oct 6, 2020Oct 6, 2020Raised $20M Series A TechCrunch
- Oct 6, 2020Oct 6, 2020New investor: Andreessen Horowitz TechCrunch
Funding History
3 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 24, 2026 | funding round | $129M | — | BioPharma Dive | |
| Jul 24, 2026 | IPO | $155.5M (incl. private placement) | — | Scribe Therapeutics | |
| Oct 6, 2020 | Series A | $20M | — | Andreessen HorowitzLeadunverified | TechCrunch |
Investors
Latest Pulse
- Jul 31, 2026The IPO Window Is Splitting Into Two Very Different TiersThis week's debuts split the 2026 IPO market sharply: differentiated biotech stories got double-digit pops, while mature, sponsor-backed consumer brands opened flat or down regardless of profitability.→
- Jul 31, 2026Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea PillApnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.→
- Jul 31, 2026Apnimed Prices Upsized IPO at $16, Raises $192MApnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.→
- Jul 30, 2026Why 2026's IPO Debuts Are Splitting Into Two TiersThis week's IPO calendar is splitting cleanly into two tiers -- AI-adjacent and clinical-stage biotech names popping double digits, while established consumer and franchise brands price cleanly but open flat or down, a divergence worth watching as the 2026 IPO window matures.→
- Jul 30, 2026Reformation Opens Flat, Valued at $886M in NYSE DebutReformation opened flat at its $15 IPO price in its NYSE debut Thursday, valuing the Permira-backed sustainable fashion brand at $886.1 million after it raised $210.9 million pricing at the bottom of its range.→
- Jul 29, 2026Goldman-Backed Attovia Sets Terms for $200M Nasdaq IPOAttovia Therapeutics set terms for a Nasdaq IPO, offering 12.5 million shares at $15-17 to raise up to $212.5 million, advancing its Phase 1 itch and eczema drug candidates toward a public listing under ticker ATTO.→
- Jul 28, 2026Why Half Of 2026's IPO Class Trades Underwater203 companies have gone public on the NYSE or Nasdaq in 2026, but roughly half now trade below their offering price -- and Tuesday's SpaceX whipsaw shows exactly why scarcity-driven IPO pops keep failing to hold.→
- Jul 28, 2026SpaceX Shares Whipsaw, Briefly Erase $1.2 TrillionSpaceX stock briefly fell more than 20% below its June IPO price on Tuesday, wiping out roughly $1.2 trillion in paper value before paring losses, as the thin public float that fueled its post-IPO pop now works in reverse.→
- Jul 28, 2026Value Add Pulse Analysis: The IPO Hype Cycle Returns203 companies have gone public on the NYSE or Nasdaq in 2026, but roughly 49% now trade below their IPO price, exposing a widening gap between opening-day demand and durable public-market performance.→
- Jul 27, 2026Why 2026's IPO Market Already Beat Goldman's BetA Value Add Pulse analysis of 2026's IPO market finds proceeds already tracking well ahead of Goldman Sachs's February forecast of $160 billion for the full year, driven by a handful of enormous AI-adjacent listings.→
Coverage Timeline
newest first- Jul 24, 2026IPOScribe Therapeutics Prices Upsized IPO With Sanofi Backing$128.7M Raised→
- Jul 23, 2026IPOScribe Therapeutics Soars In Rare Gene-Editing IPO$128.7M IPO→
- Jul 10, 2026IPODoudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO$180M+ partnership payments→
- Jul 2, 2026IPOScribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPOS-1 filed→
- Jul 2, 2026IPOScribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech AppetiteUp to $75M IPO→
All Coverage
IPO$128.7M Raised
Scribe Therapeutics Prices Upsized IPO With Sanofi Backing
Gene-editing biotech Scribe Therapeutics priced an upsized IPO at $15 per share, raising $128.7 million with Sanofi as a strategic anchor investor, the first gene-editing IPO in over two years.
Scribe Therapeutics Soars In Rare Gene-Editing IPO
IPO$128.7M IPO
Scribe Therapeutics Soars In Rare Gene-Editing IPO
Scribe Therapeutics priced an upsized $128.7 million IPO and surged in its Nasdaq debut, a rare early-stage listing for a gene-editing biotech in a market that has favored de-risked, later-stage companies.
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
IPO$180M+ partnership payments
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
IPOS-1 filed
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
Scribe Therapeutics filed its S-1 with the SEC on July 2, seeking to list on the Nasdaq Global Market under the ticker 'SCTX.' The clinical-stage biotech, co-founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna, has raised roughly $150 million in equity financing since 2017 and is advancing STX-1150 -- an epigenetic-silencing CRISPR candidate for cardiovascular disease -- through an Australian first-in-human trial, while disclosing only $49.7 million in cash and marketable securities against a $175.1 million accumulated deficit.
Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
IPOUp to $75M IPO
Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
Scribe Therapeutics filed to raise up to $75 million in a Nasdaq IPO, becoming an early test of public-market appetite for Phase 1 biotechs -- its lead candidate, a CRISPR-based epigenetic therapy targeting PCSK9 to lower LDL cholesterol, is already in a.
Related Companies
Shared investors
Scribe Therapeutics FAQ
What is Scribe Therapeutics's market cap?
Scribe Therapeutics's market cap is $542.77M (As of Sep 4, 2026, stockanalysis.com).
How much has Scribe Therapeutics raised?
Scribe Therapeutics has raised IPO gross proceeds ~$155.5M (incl. private placement) in total funding (As of Jul 27, 2026, Scribe Therapeutics).
Who are Scribe Therapeutics's investors?
Scribe Therapeutics's investors include Andreessen Horowitz, Sanofi Ventures, OrbiMed Advisors (As of Sep 4, 2026).
Is Scribe Therapeutics publicly traded?
Yes. Scribe Therapeutics trades under the ticker SCTX, with a market cap of $542.77M (As of Sep 4, 2026).
Sources & methodologyshow
Where these figures come from
- Scribe Therapeuticsprimary source2 facts
- TechCrunchmajor outlet1 fact
- stockanalysis.comresearch database1 fact
- BioPharma DiveValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.